EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Healthcare Resource Utilization and Direct Costs of Chronic Myeloid Leukemia in the Brazilian Public Health System

Johnny Wallef Leite Martins, Diogo Noin de Oliveira, André Henrique Ornelas de Oliveira, Ana Beatriz Machado de Almeida, Gustavo Pires Matheus, Alessandro Bigoni

Advances in Hematology · 2026-01 · 2026 (1)

DOI: 10.1155/ah/6620241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Hematology, online erschienen am 17.11.2026. Verfasst von Johnny Wallef Leite Martins und 5 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study evaluated healthcare resource utilization (HCRU), direct costs, and cost avoidance associated with chronic myeloid leukemia (CML) treatment within Brazil’s public healthcare system (SUS).

Methods

A retrospective observational analysis was conducted using data from Ambulatory (SIA) and Hospital (SIH) Information Systems. Adults (≥ 18 years) with at least one ICD‐10 C92.1 claim between January 2013 and December 2023 were included.

Results

A total of 13,162 patients were analyzed, predominantly male (55.0%) with a median age of 51 years (IQR: 39–63) and an average follow‐up of 4.0 years. Most patients (90.8%) were in the chronic phase. On average, patients had 42.8 outpatient visits. Hospitalization occurred in 16.7% of patients, and 10.4% required intensive care unit (ICU) care. In the chronic phase, outpatient visits averaged 31.9 in line of therapy (LOT) 1 and 16.6 in LOT3. Hospitalization and ICU rates were highest in LOT3 (12.6% and 18.5%, respectively). Total direct costs were USD 30.02M for outpatient visits, USD 1.69M for procedures, and USD 13.38M for hospitalizations. Per‐patient outpatient costs ranged from USD 1060.76 in LOT1 to USD 2895.90 in LOT3; hospitalization costs ranged from USD 2888.81 in LOT1 to USD 11,847.06 in LOT3. Cost avoidance analysis revealed that patients undergoing hematopoietic stem cell transplantation (HSCT) incurred significantly higher annual costs (USD 17,198) compared to those who did not (USD 844). Patients who experienced blast crises had annual costs of USD 3363 versus USD 913 for those without. Therapeutic failure was associated with increased costs (USD 1458 vs. USD 924 per year), highlighting the financial impact of disease progression and treatment resistance.

Conclusions

CML treatment within SUS imposes a substantial economic burden, particularly in advanced LOTs. Later LOTs and disease progression are associated with increased hospitalizations, ICU admissions, and higher costs. These findings underscore the importance of early and sustained disease control to reduce healthcare expenditures and improve patient outcomes.

Zitieren

APA

Martins, J. W. L., Oliveira, D. N. D., Oliveira, A. H. O. D., Almeida, A. B. M. D., Matheus, G. P., & Bigoni, A. (2026). Healthcare Resource Utilization and Direct Costs of Chronic Myeloid Leukemia in the Brazilian Public Health System. Advances in Hematology, 2026(1). https://doi.org/10.1155/ah/6620241

Vancouver

Martins JWL, Oliveira DND, Oliveira AHOD, Almeida ABMD, Matheus GP, Bigoni A. Healthcare Resource Utilization and Direct Costs of Chronic Myeloid Leukemia in the Brazilian Public Health System. Advances in Hematology. 2026;2026(1). doi:10.1155/ah/6620241

BibTeX
@article{Martins2026,
  author = {Martins, Johnny Wallef Leite and Oliveira, Diogo Noin de and Oliveira, André Henrique Ornelas de and Almeida, Ana Beatriz Machado de and Matheus, Gustavo Pires and Bigoni, Alessandro},
  title = {Healthcare Resource Utilization and Direct Costs of Chronic Myeloid Leukemia in the Brazilian Public Health System},
  journal = {Advances in Hematology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/ah/6620241}
}
Kostenlos starten →